🇺🇸 FDA
Patent

US 9586975

Macrocyclic salt-inducible kinase inhibitors

granted A61KA61K31/5025A61K31/519

Quick answer

US patent 9586975 (Macrocyclic salt-inducible kinase inhibitors) held by Oncodesign SA expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Oncodesign SA
Grant date
Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/5025, A61K31/519, A61P, A61P17/00